Antiretroviral Drug Market

Global Antiretroviral Drug Market Size, Share & Trends Analysis Report, By Drug Class (Protease Inhibitors, Integrase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others), Forecast (2022-2028)

Published: Mar 2022 | Report Code: OMR2026261 | Category : Pharmaceuticals | Delivery Format: /

The global antiretroviral drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Antiretrovirals are the class of drugs that are considered to be effective against the incidences of a retrovirus such as to treat HIV, in particular. The major factors that are primarily attributed to the growth of these drugs include the rising prevalence and burden of HIV infections all over the globe. According to the US Department of Health & Human Services, there were nearly 37.9 million people globally living with HIV/AIDS in 2018. An estimated 1.7 million individuals globally became newly infected with HIV in 2018.

Another key trends that drive the market growth include the increasing investment in the R&D of such drugs along with the increase in the availability of novel drugs with improved drug efficacy. These drugs are available in number of categories that majorly include integrase inhibitors, protease inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and others. Among all these, Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are likely to drive the market growth during the forecast period. Currently, antiretrovirals are considered to be the base of HIV/AIDS treatment, since there is no solid cure or a preventive vaccine available for HIV. In the case of a non-resistant strain of HIV, antiretroviral treatment can restrain the replication of HIV in the majority of cases. Thus, the presence of a huge patient pool demands anti-retroviral drugs for the treatment which is projected to drive the growth of the market during the forecast period. 

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Drug Class

Regions covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape:  Bristol-Myers Squibb Co., Gilead Sciences, Inc., and Merck & Co., Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Antiretroviral Drug Market Report by Segment

By Drug Class

  • Protease Inhibitors
  • Integrase Inhibitors
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Others

Global Antiretroviral Drug Market Report by Region

North America       

  • US
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia-Pacific    

  • China
  • Japan
  • India
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East and Africa